Cardinal Health weakness a buying opportunity, says Baird

Baird analyst Eric Coldwell said they have long posited that Cardinal Health could well absorb the loss of OptumRx given strong underlying market fundamentals, recent performance, and solid BS/CF generation; and it was confirmed today by reiteration of long-term objectives. Baird believe that valuation remains attractive and theu maintain their Outperform rating and $134 price target on Cardinal Health shares.